Difficulty: Medium
Average Score: 67%
Practice
Great caution must be exercised in the use of this drug (or drugs from the same class) in parkinsonian patients who have prostatic hypertrophy or obstructive gastrointestinal disease
Correct answer
A
Rationale
In this scenario, the correct answer is A) Benztropine. Benztropine is an anticholinergic medication commonly used to treat the extrapyramidal symptoms associated with Parkinson's disease and other movement disorders. The rationale behind great caution being exercised when using benztropine in parkinsonian patients with prostatic hypertrophy or obstructive gastrointestinal disease lies in its anticholinergic properties.
Anticholinergic drugs like benztropine can exacerbate symptoms related to prostatic hypertrophy by causing urinary retention due to their effects on smooth muscle contraction. Additionally, they can worsen obstructive gastrointestinal issues by reducing gastrointestinal motility. Therefore, in patients with these conditions, the use of anticholinergic medications like benztropine should be carefully monitored or avoided altogether.
Looking at the other options:
B) Carbidopa is a medication used in combination with levodopa to treat Parkinson's disease by preventing the peripheral breakdown of levodopa, but it is not associated with the same risks in patients with prostatic hypertrophy or obstructive gastrointestinal disease.
C) Levodopa is a precursor to dopamine and is a mainstay in the treatment of Parkinson's disease. While it can have its own set of side effects, it is not specifically contraindicated in patients with prostatic hypertrophy or obstructive gastrointestinal disease.
D) Ropinirole is a dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. It does not possess the same anticholinergic properties as benztropine, so it is not associated with the same risks in patients with prostatic hypertrophy or obstructive gastrointestinal disease.
Understanding the potential interactions and contraindications of medications is crucial for healthcare providers when managing patients with complex medical conditions like Parkinson's disease. This knowledge helps in optimizing treatment outcomes while minimizing adverse effects and complications.
Anticholinergic drugs like benztropine can exacerbate symptoms related to prostatic hypertrophy by causing urinary retention due to their effects on smooth muscle contraction. Additionally, they can worsen obstructive gastrointestinal issues by reducing gastrointestinal motility. Therefore, in patients with these conditions, the use of anticholinergic medications like benztropine should be carefully monitored or avoided altogether.
Looking at the other options:
B) Carbidopa is a medication used in combination with levodopa to treat Parkinson's disease by preventing the peripheral breakdown of levodopa, but it is not associated with the same risks in patients with prostatic hypertrophy or obstructive gastrointestinal disease.
C) Levodopa is a precursor to dopamine and is a mainstay in the treatment of Parkinson's disease. While it can have its own set of side effects, it is not specifically contraindicated in patients with prostatic hypertrophy or obstructive gastrointestinal disease.
D) Ropinirole is a dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. It does not possess the same anticholinergic properties as benztropine, so it is not associated with the same risks in patients with prostatic hypertrophy or obstructive gastrointestinal disease.
Understanding the potential interactions and contraindications of medications is crucial for healthcare providers when managing patients with complex medical conditions like Parkinson's disease. This knowledge helps in optimizing treatment outcomes while minimizing adverse effects and complications.